Jefferies Financial Group downgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a buy rating to a hold rating in a research report report published on Monday morning, 24/7 WallStreet reports. The brokerage currently has $15.00 target price on the biotechnology company’s stock, down from their previous target price of $32.00. Jefferies Financial Group also issued estimates for Atara Biotherapeutics’ FY2021 earnings at ($4.78) EPS, FY2022 earnings at ($4.33) EPS and FY2023 earnings at ($2.92) EPS.
Several other research analysts have also issued reports on ATRA. BidaskClub raised Atara Biotherapeutics from a sell rating to a hold rating in a research report on Tuesday, September 10th. Mizuho set a $43.00 target price on Atara Biotherapeutics and gave the stock a buy rating in a research report on Wednesday, September 11th. Roth Capital started coverage on Atara Biotherapeutics in a research note on Friday, September 13th. They issued a buy rating and a $30.00 price target on the stock. Cowen restated a buy rating on shares of Atara Biotherapeutics in a research note on Friday, September 13th. Finally, Wedbush restated an outperform rating on shares of Atara Biotherapeutics in a research note on Wednesday, May 29th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Atara Biotherapeutics has an average rating of Buy and an average price target of $32.71.
Shares of NASDAQ:ATRA opened at $15.23 on Monday. Atara Biotherapeutics has a 52-week low of $11.89 and a 52-week high of $43.95. The firm has a market capitalization of $805.83 million, a P/E ratio of -2.89 and a beta of 2.10. The stock has a 50 day moving average price of $13.80 and a 200-day moving average price of $24.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 7.80 and a current ratio of 7.80.
In related news, Director Eric Dobmeier purchased 2,000 shares of the business’s stock in a transaction that occurred on Thursday, June 27th. The shares were bought at an average price of $19.50 per share, for a total transaction of $39,000.00. Following the purchase, the director now directly owns 16,000 shares of the company’s stock, valued at approximately $312,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.00% of the company’s stock.
Several institutional investors have recently bought and sold shares of the stock. Manchester Capital Management LLC purchased a new stake in Atara Biotherapeutics during the 1st quarter valued at $56,000. Aperio Group LLC purchased a new stake in Atara Biotherapeutics during the 2nd quarter valued at $63,000. Marshall Wace LLP purchased a new stake in Atara Biotherapeutics during the 1st quarter valued at $284,000. Xact Kapitalforvaltning AB boosted its stake in Atara Biotherapeutics by 37.3% during the 1st quarter. Xact Kapitalforvaltning AB now owns 8,100 shares of the biotechnology company’s stock valued at $322,000 after purchasing an additional 2,200 shares during the last quarter. Finally, Bank of Montreal Can boosted its stake in Atara Biotherapeutics by 81.1% during the 2nd quarter. Bank of Montreal Can now owns 8,314 shares of the biotechnology company’s stock valued at $167,000 after purchasing an additional 3,723 shares during the last quarter. Institutional investors own 91.79% of the company’s stock.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
See Also: Hedge Funds – Risk or Reward?
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.